Biopharmaceutical company
Appears in 1 story · Last updated Oct 12, 2026
As of October 2026: Advancing imapextide, a competing GLP-1 antagonist, in Phase IIa
Post-bariatric hypoglycemia has no FDA-approved treatment. In August, Amylyx Pharmaceuticals reported that its Phase III LUCIDITY trial showed avexitide cut dangerous hypoglycemic events by 55% versus placebo (p=0.000003).
Updated Oct 12
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
